Join us next Wednesday, January 16, for our first PRSA Tar Heel event of the year.
We are holding the event at the Piedmont Triad Research Park in Winston-Salem and featuring as our guest speaker its president, Eric Tomlinson, DSc, PhD.
PTRP is one of the largest urban research parks in the United States, focused on research and innovation in bio- and life-science, information technology, and the arts, and is designated as the top economic project of the region.
Dr. Tomlinson will be addressing for us the myriad Dimensions of Innovation. What is innovation? How does it go beyond the petri dish? What communication tools are used when promoting complex stories? How does a company get its message out while still protecting its product? How can communication professionals learn from what’s happening in the fields of health and science?
The January meeting will take place January 16 at:
Wake Forest Biotech Place
575 North Patterson Ave
Winston-Salem, NC 27101
(Room 153A)
Networking starts at 11:30 a.m., and the lunch and program get underway at noon. Click to register.
ABOUT DR. TOMLINSON
Dr. Tomlinson has a background as a scientific and business leader working both in early-stage and clinical stage biotechnology companies and within a global pharmaceutical company. He has built companies and teams from their inception and fund-raising – to their development of biological and small drug / device combination products and gene therapy products. He has transacted mergers of publicly traded companies and raised both private and public equity corporate financing in addition to broad-based product licensing and commercialization agreements with major pharmaceutical companies. Tomlinson has held academic appointments in the U.S. and in Europe, including at the University of Amsterdam as professor in the department of pharmacy (1979-1983). He is (co)-author of 230 research publications in the life sciences and the pharmaceutical sciences (solution thermodynamics, drug design, site-specific drug delivery and gene therapy). He is a founder of Metaclipse Therapeutics Corporation an early-stage company developing patient- and tumor-specific immunotherapies for treating cancers and currently serves as Chairman of its Board of Directors.